Keywords
diabetes mellitus, streptozotocyne dibetes, gene therapy, gene transfer vectors.
How to Cite
Tronko, M., & Kovzun, O. (2012). The present and prospects of gene therapy for type 1 diabets. Endokrynologia, 17(4), 10-15. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/415
Abstract
The article presents the current recommendation and possible prospects for the use of gene therapy for type 1 diabetes treatment. The authors observed gene transfer methods, safety of gene therapy and biological activity of these options.
References
1. Diabetes Atlas. 5th ed. International Diabetes Federation; 2011.
2. Furlan R., Butti E., Pluchino S., Martino G. Gene therapy for autoimmune diseases // Curr. Opin. Mol. Ther. 2004, 6, N 5, 525-536.
3. Zaia J.A. The status of gene vectors for the treatment of diabetes // Cell. Biochem. Biophys. 2007, 48, N 2-3, 183-190.
4. D’Anneo A., Rood P., Bottino R. et al. Gene therapy for type 1 diabetes: is it ready for the clinic? // Immunol. Res. 2006, 36, N 1-3, 83-89.
5. Prud’homme G.J., Draghia-Akli R., Wang Q. Plasmidbased gene therapy of diabetes mellitus // Gene Ther. 2007, 14, N 7, 553-564.
6. Топорова Е.К., Гулько Т.П., Сухорада Е.М. и др. Экспериментальная генная терапия сахарного диабета 1-го типа // Журнал АМН Украины. 2010, 16, дода-
ток, 170-171.
7. Bagley J., Paez-Cortez J., Tian C., Iacomini J. Gene therapy in type 1 diabetes // Crit. Rev. Immunol. 2008, 28, N 4, 301-324.
8. Harrison P.T. Application of gene therapy in diabetes care // Infect. Disord. Drug. Targets. 2008, 8, N 2, 129-133.
9. Топорова О.К., Гулько Т.П., Кордюм В.А., Тронько М.Д. Терапевтичні ефекти, обумовлені введенням гена препроінсуліну людини мишам з експериментальним цукровим діабетом 1-го типу // Ендокринологія. 2010, 15, додаток, 72.
10. Iynedjian P.B. Molecular physiology of mammalian glucokinase // Cell. Mol. Life Sci. 2009, 66, N 1, 27-42.
11. Matschinsky F.M., Zelent B., Doliba N.M. et al. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects // Handb. Exp. Pharmacol. 2011, 203, 357-401.
12. Yang R., Newgard C.B. Hepatic expression of a targeting subunit of protein phosphatase-1 in streptozotocindiabetic rats reverses hyperglycemia and hyperphagia despite depressed glucokinase expression // J. Biol. Chem. 2003, 278, N 26, 23418-23425.
13. Chen T.H., Yeh C.T., Ho Y.P., et al. Hydrodynamicsbased transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with
limited complications in diabetic mice // Endocr. J. 2009, 56, N 6, 783-790.
14. Li Y.G., Ji D.F., Zhong S. et al. Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX- 1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxaninduced
diabetic mice // J. Ethnopharmacol. 2011, 134, N 3, 961-970.
15. Yechoor V., Liu V., Espiritu C. et al. Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes // Dev. Cell. 2009, 16, N 3, 358-373.
2. Furlan R., Butti E., Pluchino S., Martino G. Gene therapy for autoimmune diseases // Curr. Opin. Mol. Ther. 2004, 6, N 5, 525-536.
3. Zaia J.A. The status of gene vectors for the treatment of diabetes // Cell. Biochem. Biophys. 2007, 48, N 2-3, 183-190.
4. D’Anneo A., Rood P., Bottino R. et al. Gene therapy for type 1 diabetes: is it ready for the clinic? // Immunol. Res. 2006, 36, N 1-3, 83-89.
5. Prud’homme G.J., Draghia-Akli R., Wang Q. Plasmidbased gene therapy of diabetes mellitus // Gene Ther. 2007, 14, N 7, 553-564.
6. Топорова Е.К., Гулько Т.П., Сухорада Е.М. и др. Экспериментальная генная терапия сахарного диабета 1-го типа // Журнал АМН Украины. 2010, 16, дода-
ток, 170-171.
7. Bagley J., Paez-Cortez J., Tian C., Iacomini J. Gene therapy in type 1 diabetes // Crit. Rev. Immunol. 2008, 28, N 4, 301-324.
8. Harrison P.T. Application of gene therapy in diabetes care // Infect. Disord. Drug. Targets. 2008, 8, N 2, 129-133.
9. Топорова О.К., Гулько Т.П., Кордюм В.А., Тронько М.Д. Терапевтичні ефекти, обумовлені введенням гена препроінсуліну людини мишам з експериментальним цукровим діабетом 1-го типу // Ендокринологія. 2010, 15, додаток, 72.
10. Iynedjian P.B. Molecular physiology of mammalian glucokinase // Cell. Mol. Life Sci. 2009, 66, N 1, 27-42.
11. Matschinsky F.M., Zelent B., Doliba N.M. et al. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects // Handb. Exp. Pharmacol. 2011, 203, 357-401.
12. Yang R., Newgard C.B. Hepatic expression of a targeting subunit of protein phosphatase-1 in streptozotocindiabetic rats reverses hyperglycemia and hyperphagia despite depressed glucokinase expression // J. Biol. Chem. 2003, 278, N 26, 23418-23425.
13. Chen T.H., Yeh C.T., Ho Y.P., et al. Hydrodynamicsbased transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with
limited complications in diabetic mice // Endocr. J. 2009, 56, N 6, 783-790.
14. Li Y.G., Ji D.F., Zhong S. et al. Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX- 1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in alloxaninduced
diabetic mice // J. Ethnopharmacol. 2011, 134, N 3, 961-970.
15. Yechoor V., Liu V., Espiritu C. et al. Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes // Dev. Cell. 2009, 16, N 3, 358-373.
Downloads
Download data is not yet available.